Pharmacology of nasal applied mupirocin in healthy volunteers: single-centre study. MUPIPHARM STUDY

2024-516309-21-00 Human pharmacology (Phase I) - Other Ended

End 30 Oct 2025 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 60
Countries 1
Sites 1

healthy volunteer

Key facts

Sponsor
Centre Hospitalier Universitaire De Saint Etienne
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Bacterial Infections and Mycoses [C01]
Trial duration
completed 30 Oct 2025
Decision date (initial)
2024-08-30
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516309-21-00
EudraCT number
2020-006105-30

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

healthy volunteer

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Hospitalier Universitaire De Saint Etienne

Sponsor organisation
Centre Hospitalier Universitaire De Saint Etienne
Address
25 Boulevard Pasteur
City
Saint-Etienne
Postcode
42100
Country
France

Scientific contact point

Organisation
Centre Hospitalier Universitaire De Saint Etienne
Contact name
project manager

Public contact point

Organisation
Centre Hospitalier Universitaire De Saint Etienne
Contact name
project manager

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 60 1
Rest of world 0

Investigational sites

France

1 site · Ended
Centre Hospitalier Universitaire De Saint Etienne
Département Infectiologie, 25 Boulevard Pasteur, 42100, Saint-Etienne

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-10 France Acceptable
2024-08-29
2024-08-30
2 SUBSTANTIAL MODIFICATION SM-1 2024-10-16 France Acceptable
2024-11-22
2024-11-22